Company Overview

CytoDyn is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn’s lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments.

CytoDyn CEO Highlights PRO 140 for Investors

Interview focused on company milestones, a pending acquisition and an array of new indications beyond the expected FDA approval for HIV treatment

View Video
CytoDyn CEO Highlights PRO 140 for Investors
View Detailed Stock Data

Stock Info

CYDY Symbol
OTCQB Market
Market Cap

Upcoming Events

Investment Community Conference Call

December 12, 2018 at 4:00 pm ET / 1:00 pm PT

Interested participants and investors may access this conference call by dialing 877-407-2986 (U.S./Canada) or 201-378-4916 (international).

A replay of the conference call will be available until February 12, 2019. To access the replay, interested parties may dial 877-660-6853 (U.S./Canada) or 201-612-7415 (international) and enter conference identification number 13683202.


Recent Events

11th Annual LD Micro Main Event

December 4, 2018 at 10:30 am PT


View Press Releases

Recent News